THORACIC SURGERY ONCOLOGY GROUP NEWS  FALL 2023

A collaboration between AATS and Memorial Sloan Kettering Cancer Center

FROM THE TSOG CHAIR
TSOG continues to push the envelope and remain relevant. In this issue, we will take a look at TSOG’s reaching target accrual of one of its first investigator-initiated trials. This is in part due to the efforts of the TSOG Investigators and Site Coordinators. TSOG has expanded to include 32 sites in total, welcoming new sites University of Minnesota (PI, Ilitch Gutierrez, MD); New York Presbyterian Hospital/Weill Cornell Medical Center (PI, Nasser Altorki, MD); Mayo Clinic-Jacksonville (PI, Ian Makey, MD); McGill University (PI, Jonathan Spicer, MD); NorthShore University HealthSystem (PI, Seth Krantz, MD); and University of Chicago (PI, Jessica Donington, MD). In this newsletter, we celebrate the TSOG 102 GGO Study (PI, James Huang, MD). This is the first TSOG study that has reached target accrual. We will also share plans to increase TSOG’s social media presence.

—David R. Jones

IN THIS ISSUE
TSOG 102 GGO Study Reaches Target Accrual  Page 2
Update on Current TSOG Trials  Page 3
TSOG Social Media Presence  Page 4
TSOG 102 GGO Study Reaches Target Accrual

**TSOG 102**

“Registry trial for the active surveillance for multifocal ground glass opacities (GGOs),” led by Dr. James Huang, from Memorial Sloan Kettering Cancer Center, has reached its target accrual (N=330). Twenty-one TSOG sites across North America accrued patients to this trial. This is the first clinical trial that TSOG has finished, and credit goes to the investigators and their teams who put patients on trial. The most recent site activations were located at the University of Pennsylvania (study PI, Doraid Jarrar, MD), Fox Chase Cancer Center (study PI, Stacy Su, MD), and New York Presbyterian Hospital/Weill Cornell Medical Center (study PI, Nasser Altorki, MD). Championed by study PI Matthew Rochefort, MD, Brigham and Women’s Hospital is the second highest accruing TSOG site for this trial, with 34 patients on study since its activation in September 2020. Patients on study will still need to be followed up as part of the trial protocol, so our work is not done. Dr. Huang is working on an abstract of the study, which will be available for review by 2024, so please continue following up on data requests in a timely fashion. It is nice to celebrate the first completed clinical trial from AATS-MSK TSOG. It is a milestone for TSOG and the AATS in that it is an achievement that has never been attempted, much less completed, by any other thoracic surgical association or society. To read more about this study’s accomplishments, please see [this AATS press release](#).
**TSOG 101**
“Evaluation of perioperative circulating tumor DNA analysis as a prognostic biomarker in patients undergoing neoadjuvant therapy for resectable non-small cell lung cancer,” led by Dr. James Isbell, from Memorial Sloan Kettering Cancer Center, is open to accrual at 15 sites, with hopes of closing in 2023. As of June 2023, there are 86 patients on study across all sites. Most recently, TSOG 101 opened to accrual at West Virginia University (study PI, Alper Toker, MD) and Mayo Clinic—Jacksonville (study PI, Ian Makey, MD). Since the study’s activation in June 2021, the University of Montreal has accrued 21 patients and continues to maintain the title as second highest accruing site, with PI Moishe Liberman, MD.

**TSOG 103**
Since Winter 2021, “The role of multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer,” led by Dr. Mara Antonoff, from MD Anderson Cancer Center, has continued to expand, with an activation at Baylor College of Medicine. After the study’s activation in July 2021, Thomas Jefferson University is the second highest accruing site, with 4 patients on study. By the end of 2022, the trial closed at sites due to low accrual. Current patients on study will be followed for survival. As of November 2023, the trial has 46 patients on study across all sites.

The PI feels there is still useful data from the accrued patients and will look into possibly reframing the study aims on the basis of the data collected.

**TSOG 105**
“Comparing the effectiveness of surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer (SORT),” a previous TSOG proposal, led by Dr. Benjamin Kozower, from Washington University, is open to accrual at the following participating TSOG sites: Washington University, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, University of Toronto/University Health Network, and Duke University. There will be a total of 8 sites.
participating in this trial, which includes non-TSOG sites Cleveland Clinic, Emory University, and Carle Clinic. This NCI-funded, multicenter, prospective cohort study is designed to compare the effectiveness of surgery versus SBRT on stakeholder-selected outcomes in patients with clinical stage I NSCLC.

As of November 2023, the study has 189 patients on study at all sites. Since the study’s activation in July 2022, Washington University leads accrual with 106 patients on study. This is followed by Memorial Sloan Kettering Cancer Center as the second highest accruing site, which has 30 patients on study since activation at the site in November 2022. The trial’s Research Team Site Coordinators meet monthly on the first Monday of each month, and study PIs meet quarterly, with their last meeting held in October 2023.

Visit TSOG Soon on X, Formerly Known as Twitter
TSOG would like to increase its social media presence. We would like to do this by using X, formerly known as Twitter, as a platform to communicate news and information about TSOG and to encourage public awareness of the group and thereby expand membership. Stay tuned @TSOG_ClinTrials.

You Can NOW Visit the AATS/TSOG Webpages
The TSOG website provides a brief description of TSOG, our trials, participating sites, Executive Board, administrative and staff contacts, and newsletters. Feel free to visit the site today.
https://www.aats.org/about-the-aats/thoracic-surgical-oncology-group